Trials / Terminated
TerminatedNCT00804973
Study in Participants With Acute Migraines Headaches
A Safety, Tolerability, and Efficacy Study of LY2590443 in the Treatment of Acute Migraine Headache
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2590443 | 200 milligrams (mg) as four 50-mg capsules, oral, once |
| DRUG | Placebo injection | saline solution, injection, once |
| DRUG | Sumatriptan | 6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once |
| DRUG | Placebo capsule | 4 capsules, once |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2008-12-09
- Last updated
- 2020-05-19
- Results posted
- 2020-05-19
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00804973. Inclusion in this directory is not an endorsement.